Royalty Pharma falls after investing $250 mln in Biogen's lupus treatment

Royalty Pharma

12/02/2025 15:07

** Shares of biotech investor Royalty Pharma  RPRX.O  fall
1.3% to $31.81
    ** RPRX says it is providing up to $250 mln in funding to
Biogen  BIIB.O  to support the development of litifilimab, a
potential treatment for systemic lupus erythematosus (SLE) and
cutaneous lupus erythematosus (CLE)
    ** SLE and CLE are two forms of the autoimmune disease lupus
that affect multiple organs and the skin, respectively, and is
currently in late-stage trial
    ** RPRX says the funding will be provided over six quarters
in exchange for regulatory milestones and royalties on future
worldwide sales of litifilimab
    ** Late-stage trial data are expected between 2026 and 2027
    ** RPRX fell 9.8% in 2024

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))